论文部分内容阅读
美国食品药品监督管理局(FDA)2012年9月28日公布批准Humira(阿达木单抗)扩大适应证,批准其用于治疗成人患者中至重度溃疡性结肠炎。Humira被批准用于免疫抑制剂类的药物如皮质激素、硫唑嘌呤、6-巯嘌呤无效时的溃疡性结肠炎的治疗。该药是一种抗肿瘤坏死因子(TNF)拮抗剂可阻断在异常炎性反应和免疫应答中产生重要作用的蛋白质。溃疡性结肠炎是一种慢性疾病,可引起大肠腔内部出现炎症和溃疡。它是常见的两种主要的慢性炎症性肠疾病之一,按
The U.S. Food and Drug Administration (FDA) announced on September 28, 2012 the approval of the Humira (Adalimumab) extended indication for its approval for the treatment of severe ulcerative colitis in adult patients. Humira is approved for the treatment of ulcerative colitis when immunosuppressants such as corticosteroids, azathioprine and 6-mercaptopurine are ineffective. This drug is a protein that is an anti-tumor necrosis factor (TNF) antagonist that blocks the important effects that occur in abnormal inflammatory and immune responses. Ulcerative colitis is a chronic disease that can cause inflammation and ulcers inside the large intestine. It is one of two major chronic inflammatory bowel diseases that are common, according to